Page last updated: 2024-12-05

metformin hydrochloride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Metformin hydrochloride is a biguanide drug primarily used to treat type 2 diabetes. It is synthesized by a multi-step process involving the reaction of guanidine with 2-chlorophenoxymethyl-N-methyl-N-(1-phenylethyl)amine. Metformin lowers blood glucose levels by inhibiting hepatic gluconeogenesis and increasing insulin sensitivity. Its importance lies in its ability to manage blood sugar and reduce the risk of complications associated with type 2 diabetes. It is extensively studied due to its potential anti-cancer properties, cardiovascular benefits, and its use in the treatment of other conditions like polycystic ovary syndrome (PCOS).'

metformin hydrochloride : A hydrochloride resulting from the reaction of metformin with one molar equivalent of hydrogen chloride. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID14219
CHEMBL ID1703
CHEBI ID6802
SCHEMBL ID22977
SCHEMBL ID10325580
SCHEMBL ID20140191
MeSH IDM000604093

Synonyms (242)

Synonym
biguanide,1-dimethyl-, monohydrochloride
metformin monohydrochloride
diabefagos
n,n-dimethylbiguanide hydrochloride
imidodicarbonimidic diamide,n-dimethyl-, monohydrochloride
meguan
d 15095
nsc-91485
nsc91485
la 6063
dmbg hydrochloride
dimethylbiguanide hydrochloride
n1,n1-dimethylbiguanide hydrochloride
la 6023
AC-2075
786z46389e ,
metformin hcl er
ec 214-230-6
metformin hydrochloride [usan:usp:jan]
cidophage
unii-786z46389e
d.b.i.
smr000058277
MLS000028493 ,
siofor
diabex
glifage
diabetosan
glucomet
dextin
geamet
glumetza
fornidd
1,1-dimethylbiguanide monohydrochloride
apo-metformin
n,n-dimethylimidodicarbonimidic diamide hydrochloride
glucophage-mite
nsc 91485
islotin retard
glucofago
glyformin
dabex
glupermin
glycoran
siamformet
denkaform
walaphage
imidodicarbonimidic diamide, n,n-dimethyl-, monohydrochloride
risidon
meglucon
glucophage 850
hsdb 7080
diformin retard
glucophage xr
novo-metformin
glucophage forte
diformin
glibomet
metforal
metiguanide monohydrochloride
diabetex
mescorit
glucoliz
biguanide, 1,1-dimethyl-, monohydrochloride
riomet
1,1-dimethylbiguanide hydrochloride
haurymellin hydrochloride
diamin
c4h11n5.hcl
diaformin
glucophage retard
metbay
diabesin
benofomin
glyciphage
biocos
gluconil
metomin
glucomine
diaphage
metformin hydrochloride [usan]
glucoform
thiabet
metolmin
einecs 214-230-6
fortamet
biguanide, 1,1-dimethyl-, hydrochloride
ai3-51264
diaberit
diabetmin
glucophage
dmgg hydrochloride
gluformin
metformin hcl
1115-70-4
PRESTWICK_519
metformin hydrochloride
NCGC00016564-01
cas-1115-70-4
1,1-dimethylbiguanide hydrochloride, 97%
glucophage (tn)
metformin hydrochloride (jp17/usp)
D00944
NCGC00095185-01
1,1-dimethylbiguanide, hydrochloride
NCGC00095185-02
SPECTRUM1505814
hydrochloride, metformin
hcl, metformin
MLS002222221
neodipa
CHEMBL1703
chebi:6802 ,
ex-404
ex404
apophage
glucaminol
HMS1568A09
HMS1922H14
nsc759262
pharmakon1600-01505814
nsc-759262
tox21_110498
dtxcid7017246
dtxsid9037246 ,
M2009
c4h12cln5
BP-12830
FT-0628265
S1950
AKOS015894259
metformin hydrochloride [orange book]
metformin hydrochloride component of qternmet xr
metformin hydrochloride component of actoplus met
qternmet component metformin hydrochloride
metformin hydrochloride [jan]
metformin hydrochloride component of metaglip
actoplus met component metformin hydrochloride
metformin hydrochloride component of janumet
segluromet component metformin hydrochloride
kombiglyze xr component metformin hydrochloride
trijardy xr component metformin hydrochloride
metformin hydrochloride component of trijardy xr
metformin hydrochloride [ep monograph]
metformin hydrochloride component of segluromet
metformin hydrochloride [ema epar]
metformin hydrochloride [usp-rs]
qternmet xr component metformin hydrochloride
metformin hydrochloride [vandf]
metformin hydrochloride [hsdb]
metformin hydrochloride [who-dd]
invokamet component metformin hydrochloride
metformin hydrochloride component of synjardy
metformin hydrochloride [usp monograph]
metformin hydrochloride component of qternmet
metformin hydrochloride component of xigduo
metformin hydrochloride component of glucovance
riomet er
metformin hydrochloride [mi]
metformin hydrochloride [mart.]
jentadueto component of metformin hydrochloride
metformin hydrochloride component of invokamet
glucovance component metformin hydrochloride
metformin hydrochloride component of kombiglyze xr
metformin hydrochloride component of jentadueto
metformin hydrochloride component of kazano
kazano component metformin hydrochloride
xigduo component metformin hydrochloride
janumet component metformin hydrochloride
metaglip component metformin hydrochloride
CCG-208004
metformin (hydrochloride)
HY-17471A
CS-1851
SCHEMBL22977
NCGC00016564-06
tox21_110498_1
KS-1272
OETHQSJEHLVLGH-UHFFFAOYSA-N
mfcd00012582
SY001217
F2173-0894
Q-201360
SCHEMBL10325580
metformin hydrochloride, british pharmacopoeia (bp) reference standard
3-(diaminomethylidene)-1,1-dimethylguanidine;hydrochloride
HB2153
15537-72-1
1, 1-dimethylbiguanide hydrochloride
metformin hydrochloride, united states pharmacopeia (usp) reference standard
metformin hydrochloride, pharmaceutical secondary standard; traceable to usp and pheur
n',n'-dimethylbiguanide hydrochloride
SR-05000001764-2
1 1-dimethylbiguanide hydrochloride
metformin hydrochloride, pharmaceutical secondary standard; certified reference material
metformin hydrochloride, european pharmacopoeia (ep) reference standard
metformin hydrochloride 1.0 mg/ml in methanol (as free base)
1-dimethylbiguanide hydrochloride
1-carbamimidamido-n,n-dimethylmethanimidamide hydrochloride
(e)-2-carbamimidoyl-1,1-dimethylguanidine hydrochloride
Z2244578658
BCP03594
metformin hydrochloride (glucophage)
metformin hcl(glucophage)
imidodicarbonimidic diamide, n,n-dimethyl-, hydrochloride (1:2)
1674364-49-8
metformin hydrochloride,(s)
Q27089363
SCHEMBL20140191
SB19704
metformin hydrochloride (mm/ml)
n-[amino(dimethylamino)methylidene]guanidine hydrochloride
AKOS037515743
metforminhydrochloride
BM164663
1-[(diaminomethylidene)amino]-n,n-dimethylmethanimidamide hydrochloride
EN300-30323
(e)-n-[amino(dimethylamino)methylidene]guanidine hydrochloride
EN300-26258648
[(e)-[amino(dimethylamino)methylidene]amino]methanimidamide hydrochloride
metformin hydrochoride
metformin hydrochloride (usan:usp:jan)
metformin hydrochloride tablet
glucophage er
metformin hydrochloride (mart.)
metformin-hcl
metformin hydrochlorideer
metformin hydrochloride (usp-rs)
dimefor
metformin hydrochloride oral solution
n,n-dimethylimidodicarbonimidic diamide monohydrochloride
metformin hydrochloride (ep monograph)
metformin hydrochloride extended-release tablets
metformin hydrochloride er
metformin hydrochloride extended-release
metformin hydrochloride extended-release 500mg
metformin hydrochloride (usp monograph)
metformin hydrochloridee/r
glucoformin
metformin er 500 mg
compresso mf 95p
metformin er 750 mg

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" The enhanced oral absorption consequently promoted the bioavailability of metformin from 43% to 65% in rats."( The first bioreversible prodrug of metformin with improved lipophilicity and enhanced intestinal absorption.
Huttunen, KM; Järvinen, T; Kemppainen, E; Laine, K; Leppänen, J; Mannila, A; Rautio, J; Vepsäläinen, J, 2009
)
0.35
" Oral bioavailability was not affected (F = 64 ± 4 versus 59 ± 11; knockout versus wild type)."( Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
Bedwell, DW; Higgins, JW; Zamek-Gliszczynski, MJ, 2012
)
0.38
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
environmental contaminantAny minor or unwanted substance introduced into the environment that can have undesired effects.
hypoglycemic agentA drug which lowers the blood glucose level.
xenobioticA xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
hydrochlorideA salt formally resulting from the reaction of hydrochloric acid with an organic base.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (12)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency112.20200.044717.8581100.0000AID485294
TDP1 proteinHomo sapiens (human)Potency2.85710.000811.382244.6684AID686979
AR proteinHomo sapiens (human)Potency1.47680.000221.22318,912.5098AID743040; AID743042; AID743054
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency3.23950.000214.376460.0339AID720691; AID720692; AID720719
estrogen nuclear receptor alphaHomo sapiens (human)Potency0.45560.000229.305416,493.5996AID743069; AID743075; AID743091
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency1.43000.001723.839378.1014AID743083
huntingtin isoform 2Homo sapiens (human)Potency11.22020.000618.41981,122.0200AID1688
gemininHomo sapiens (human)Potency0.07310.004611.374133.4983AID624296
TAR DNA-binding protein 43Homo sapiens (human)Potency1.00001.778316.208135.4813AID652104
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
streptokinase A precursorStreptococcus pyogenes M1 GASEC50 (µMol)77.82450.06008.9128130.5170AID1902; AID1914
Estrogen receptorRattus norvegicus (Norway rat)EC50 (µMol)150.00000.006022.3670130.5170AID1914
Estrogen receptor betaRattus norvegicus (Norway rat)EC50 (µMol)150.00000.006022.3670130.5170AID1914
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (18)

Processvia Protein(s)Taxonomy
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Processvia Protein(s)Taxonomy
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (112)

Assay IDTitleYearJournalArticle
AID1210808Antidiabetic activity in Oct1/Oct2-knockout FVB mouse assessed as reduction in blood glucose level at 300 mg/kg, po by oral glucose tolerance test relative to control2012Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6
Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
AID739350Activation of AMPK in triple-negative human Hs575T cells at 20 mM after 24 hrs by immunoblot analysis2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
A novel metformin derivative, HL010183, inhibits proliferation and invasion of triple-negative breast cancer cells.
AID1210798Drug recovery in Oct1/Oct2-knockout FVB mouse urine assessed as corrected compound recovery by measuring nominal to observerd glomerular filtration rate ratio at 5 mg/kg, iv2012Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6
Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
AID739357Antiinvasive activity against triple-negative human Hs578T cells at 20 mM after 17 hrs by light microscopic analysis2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
A novel metformin derivative, HL010183, inhibits proliferation and invasion of triple-negative breast cancer cells.
AID1210804Drug uptake in Oct1/Oct2-knockout FVB mouse kidney at at 10 to 300 mg/kg, po after 1.5 to 2.5 hrs2012Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6
Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
AID1210820Volume of distribution in human2012Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6
Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
AID1210807Antidiabetic activity in wild type FVB mouse assessed as reduction in blood glucose level at 300 mg/kg, po by oral glucose tolerance test relative to control2012Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6
Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
AID1210813Antidiabetic activity in wild type FVB mouse assessed as half-maximal efficacious AUC at 300 mg/kg, po by oral glucose tolerance test relative to control2012Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6
Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1210818Oral bioavailability in human2012Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6
Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
AID1210852Creatinine renal clearance in Oct1/Oct2-knockout FVB mouse at 5 mg/kg, iv2012Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6
Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
AID1210850Terminal half life in Oct1/Oct2-knockout FVB mouse at 5 mg/kg, iv2012Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6
Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
AID739354Antiinvasive activity against triple-negative human Hs578T cells assessed as downregulation of MMP2 level after 24 hrs by gelatin zymogram assay2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
A novel metformin derivative, HL010183, inhibits proliferation and invasion of triple-negative breast cancer cells.
AID1210819Oral bioavailability in mouse2012Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6
Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
AID1210809Antidiabetic activity in po dosed wild type FVB mouse assessed as reduction in blood glucose level by oral glucose tolerance test relative to control2012Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6
Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
AID1210816Antidiabetic activity in Oct1/Oct2-knockout FVB mouse assessed as plasma insulin level at 300 mg/kg, po by oral glucose tolerance test2012Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6
Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
AID1210797Inulin renal clearance in Oct1/Oct2-knockout FVB mouse at 5 mg/kg, iv2012Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6
Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
AID1210822Permeability of the compound by PAMPA2012Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6
Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
AID1210848Clearance in Oct1/Oct2-knockout FVB mouse at 5 mg/kg, iv2012Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6
Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
AID1210811Antidiabetic activity in wild type FVB mouse assessed as blood glucose AUC level at 300 mg/kg, po by oral glucose tolerance test relative to control2012Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6
Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
AID1210812Antidiabetic activity in Oct1/Oct2-knockout FVB mouse assessed as blood glucose AUC level at 300 mg/kg, po by oral glucose tolerance test relative to control2012Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6
Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
AID99690lowest concentration at which glucose utilized was greater than or equal to 140% of control value tested in a glucose utilization L6 myocyte in vitro assay1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
Substituted tetrahydropyrrolo[2,1-b]oxazol-5(6H)-ones and tetrahydropyrrolo[2,1-b]thiazol-5(6H)-ones as hypoglycemic agents.
AID1210836Clearance in wild type FVB mouse at 5 mg/kg, iv2012Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6
Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
AID1210843Oral bioavailability in wild type FVB mouse at 10 to 300 mg/kg2012Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6
Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
AID1210846AUC (0 to infinity) in Oct1/Oct2-knockout FVB mouse at 5 mg/kg, iv2012Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6
Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
AID739348Inhibition of mTOR phosphorylation in triple-negative human Hs575T cells at 20 mM after 24 hrs by immunoblot analysis2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
A novel metformin derivative, HL010183, inhibits proliferation and invasion of triple-negative breast cancer cells.
AID1210840Creatinine renal clearance in wild type FVB mouse at 5 mg/kg, iv2012Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6
Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
AID739641Induction of apoptosis in triple-negative human MDA-MB-231 cells assessed as viable cells at 10 mM after 24 hrs by annexin V-FITC/propidium iodide staining-based flow cytometric analysis relative to control2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
A novel metformin derivative, HL010183, inhibits proliferation and invasion of triple-negative breast cancer cells.
AID739647Cytotoxicity against triple-negative human MDA-MB-231 cells assessed as growth inhibition after 24 hrs by MTT assay2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
A novel metformin derivative, HL010183, inhibits proliferation and invasion of triple-negative breast cancer cells.
AID1210815Antidiabetic activity in wild type FVB mouse assessed as plasma insulin level at 300 mg/kg, po by oral glucose tolerance test2012Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6
Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
AID1210814Antidiabetic activity in Oct1/Oct2-knockout FVB mouse assessed as half-maximal efficacious AUC at 300 mg/kg, po by oral glucose tolerance test relative to control2012Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6
Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
AID1210805Antidiabetic activity in wild type FVB mouse assessed as reduction in blood glucose level at 10 mg/kg, po by oral glucose tolerance test2012Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6
Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
AID1210799Oral bioavailability in Oct1/Oct2-knockout FVB mouse at 10 to 300 mg/kg2012Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6
Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
AID1210802Drug uptake in Oct1/Oct2-knockout FVB mouse liver at 100 to 300 mg/kg, po after 1.5 to 2.5 hrs2012Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6
Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
AID739362Induction of apoptosis in triple-negative human MDA-MB-231 cells assessed as dead cells at 10 mM after 24 hrs by annexin V-FITC/propidium iodide staining-based flow cytometric analysis relative to control2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
A novel metformin derivative, HL010183, inhibits proliferation and invasion of triple-negative breast cancer cells.
AID1210810Antidiabetic activity in po dosed Oct1/Oct2-knockout FVB mouse assessed as reduction in blood glucose level by oral glucose tolerance test relative to control2012Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6
Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
AID1210845AUC (0 to t) in Oct1/Oct2-knockout FVB mouse at 5 mg/kg, iv2012Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6
Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
AID1210834AUC (0 to infinity) in wild type FVB mouse at 5 mg/kg, iv2012Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6
Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID739353Antiinvasive activity against triple-negative human Hs578T cells assessed as downregulation of MMP2 level by immunoblot analysis2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
A novel metformin derivative, HL010183, inhibits proliferation and invasion of triple-negative breast cancer cells.
AID1210839Drug excretion in wild type FVB mouse urine at 5 mg/kg, iv after 2 hrs2012Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6
Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
AID1210800Tmax in Oct1/Oct2-knockout FVB mouse at 10 to 300 mg/kg, po2012Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6
Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
AID1210821Lipophilicity, log D of the compound2012Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6
Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
AID1210842Drug recovery in wild type FVB mouse urine assessed as corrected compound recovery by measuring nominal to observerd glomerular filtration rate ratio at 5 mg/kg, iv2012Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6
Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
AID739648Cytotoxicity against triple-negative human Hs578T cells assessed as growth inhibition after 24 hrs by MTT assay2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
A novel metformin derivative, HL010183, inhibits proliferation and invasion of triple-negative breast cancer cells.
AID739642Induction of apoptosis in triple-negative human MDA-MB-231 cells assessed as apoptotic cells at 10 mM after 24 hrs by annexin V-FITC/propidium iodide staining-based flow cytometric analysis relative to control2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
A novel metformin derivative, HL010183, inhibits proliferation and invasion of triple-negative breast cancer cells.
AID1210844Tmax in wild type FVB mouse at 10 to 300 mg/kg, po2012Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6
Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
AID420770Dissociation constant, pKa of the compound2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
The first bioreversible prodrug of metformin with improved lipophilicity and enhanced intestinal absorption.
AID739640Induction of apoptosis in triple-negative human MDA-MB-231 cells assessed as early apoptotic cells at 10 mM after 24 hrs by annexin V-FITC/propidium iodide staining-based flow cytometric analysis relative to control2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
A novel metformin derivative, HL010183, inhibits proliferation and invasion of triple-negative breast cancer cells.
AID739358Antiinvasive activity against triple-negative human Hs578T cells at 10 mM after 17 hrs by light microscopic analysis2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
A novel metformin derivative, HL010183, inhibits proliferation and invasion of triple-negative breast cancer cells.
AID1210837Volume of distribution at steady state in wild type FVB mouse at 5 mg/kg, iv2012Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6
Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
AID1210841Inulin renal clearance in wild type FVB mouse at 5 mg/kg, iv2012Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6
Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
AID1210801Drug uptake in wild type FVB mouse liver at 100 to 300 mg/kg, po after 1.5 to 2.5 hrs2012Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6
Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
AID1210817Volume of distribution in mouse2012Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6
Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
AID1210806Antidiabetic activity in Oct1/Oct2-knockout FVB mouse assessed as reduction in blood glucose level at 10 mg/kg, po by oral glucose tolerance test2012Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6
Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
AID1210803Drug uptake in wild type FVB mouse kidney at at 10 to 300 mg/kg, po after 1.5 to 2.5 hrs2012Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6
Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
AID1210847Initial plasma concentration in Oct1/Oct2-knockout FVB mouse at 5 mg/kg, iv2012Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6
Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
AID1210851Drug excretion in Oct1/Oct2-knockout FVB mouse urine at 5 mg/kg, iv after 2 hrs2012Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6
Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
AID1210833AUC (0 to t) in wild type FVB mouse at 5 mg/kg, iv2012Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6
Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
AID1210849Volume of distribution at steady state in Oct1/Oct2-knockout FVB mouse at 5 mg/kg, iv2012Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6
Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
AID739340Toxicity in BALB/c athymic nude mouse xenografted with triple-negative human MDA-MB-231 cells assessed as body weight change at 500 mg/kg, po qd measured for 35 days relative to vehicle-treated control2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
A novel metformin derivative, HL010183, inhibits proliferation and invasion of triple-negative breast cancer cells.
AID1210838Terminal half life life in wild type FVB mouse at 5 mg/kg, iv2012Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6
Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
AID739351Antiinvasive activity against triple-negative human Hs578T cells assessed as downregulation of MMP9 level at 5 to 20 mM after 24 hrs by gelatin zymogram assay2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
A novel metformin derivative, HL010183, inhibits proliferation and invasion of triple-negative breast cancer cells.
AID1210835Initial plasma concentration in wild type FVB mouse at 5 mg/kg, iv2012Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 40, Issue:6
Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (22)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (4.55)18.2507
2000's2 (9.09)29.6817
2010's12 (54.55)24.3611
2020's7 (31.82)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 112.19

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index112.19 (24.57)
Research Supply Index3.14 (2.92)
Research Growth Index5.28 (4.65)
Search Engine Demand Index199.24 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (112.19)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (4.55%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other21 (95.45%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]